Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Announces FY2005 Results; On Track for Bacterial Analysis System

NEW YORK, Nov. 2 (GenomeWeb News) - Accelr8 Technology had increased revenues in its fiscal year 2005 results, which ended July 31, the company said this morning.


The Denver-based company reported sales of its OptiChem microarraying slides had nearly tripled to $336,610 for the fiscal year. The slides accounted for 67% of the company's total revenue. For the fourth quarter, the company's total revenues increased to approximately $118,000 from $33,100 the previous year.


Fourth quarter R&D costs were approximately $485,000, a significant increase from $146,000 during the same quarter last year. The company attributed the increase to continued work on its BACcelr8r rapid bacterial analysis system.


"We've installed our first in-house research version of the BACcerlr8r," said David Howson, Accelr8's president in a statement. "We also started the engineering design on the next generation of the research platform."


Accelr8's fiscal year net losses totaled $2 million, or $.21 per share, compared to a loss of $909,421 or $.09 per share the previous year.


As of July 31, Accelr8 had $5.6 million in cash and cash equivalents.



The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.